Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 2/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.35 |
| ▸ | CLK2 | P49760 | 1/20 | 0.33 |
| ▸ | CLK3 | P49761 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4887340 | 0.69 | PDE3B (0.45) | CDK5CDK5R1MEN1ALDH1A1HPGD | |
| SCHEMBL10808931 | 0.67 | PDE3B (0.68) | CDK5CDK5R1TDO2PDE3BPDE3A | |
| SCHEMBL4887297 | 0.66 | PIK3CD (0.52) | POLBMEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL4888662 | 0.65 | CLK2 (0.42) | TDO2HPGDCLK2CLK3DYRK1A | |
| SCHEMBL4888763 | 0.64 | PDE3B (0.51) | POLBMEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL6435016 | 0.64 | PDE3B (0.49) | CDK5CDK5R1TDO2POLBMEN1 | |
| SCHEMBL6432302 | 0.63 | KDM4E (0.59) | MEN1ALDH1A1HPGDKMT2ACA1 | |
| SCHEMBL4886299 | 0.63 | HSD17B10 (0.54) | MEN1ALDH1A1HPGDKMT2AHSD17B10 | |
| SCHEMBL4887564 | 0.62 | PDE3B (0.45) | MEN1ALDH1A1HPGDKMT2APLAT | |
| SCHEMBL22347416 | 0.62 | CA1 (0.51) | POLBALDH1A1HPGDCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275075-A1 | Medicine Comprising a Combination of an Acetylcholinesterase Inhibitor and a 5-Substituted-3-Oxadiazolyl-1,6-Naphthyridin-2(1H)-One Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-11-06 | — | — | US | claimed |
| EP-1736155-A1 | MEDICINE COMPRISING COMBINATION OF ACETYLCHOLINE ESTERASE INHIBITOR AND 5-SUBSTITUTED 3-OXADIAZOLYL-1,6-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-27 | — | — | EP | claimed |
| EP-1010699-B1 | 5-SUBSTITUTED-3-OXADIAZOLYL-1,6-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVES | DAINIPPON PHARMACEUTICAL CO (JP) | 2005-06-15 | — | — | EP | claimed |
| US-6743803-B2 | SUCH AS ALZHEIMER'S DISEASE AND SCHIZOPHRENIA DUE TO HYPOFUNCTION OF GLUTAMIC ACID RECEPTOR; 5-SUBSTITUTED-3-OXADIAZOLYL-1,6-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVES | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-06-01 | — | — | US | claimed |
| US-20030166673-A1 | Medicines for the prevention and treatment of neurodegenerative diseases | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2003-09-04 | — | — | US | claimed |
| EP-1295883-A1 | MEDICINES FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | Dainippon Pharmaceutical Co., Ltd. (JP) | 2003-03-26 | — | — | EP | claimed |
| US-6172079-B1 | BENZODIAZEPINE INVERSE AGONISTS; ALZHEIMER*S DISEASE; ANXIOLYTIC AGENTS, SEDATIVES, MUSCLE RELAXANTS, ANTIEPILEPTIC AGENTS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2001-01-09 | — | — | US | claimed |
| EP-1010699-A1 | 5-SUBSTITUTED-3-OXADIAZOLYL-1,6-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVES | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2000-06-21 | — | — | EP | claimed |
| US-20080275075-A1 | Medicine Comprising a Combination of an Acetylcholinesterase Inhibitor and a 5-Substituted-3-Oxadiazolyl-1,6-Naphthyridin-2(1H)-One Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-11-06 | — | — | US | disclosed |
| EP-1736155-A1 | MEDICINE COMPRISING COMBINATION OF ACETYLCHOLINE ESTERASE INHIBITOR AND 5-SUBSTITUTED 3-OXADIAZOLYL-1,6-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-27 | — | — | EP | disclosed |
| EP-1010699-B1 | 5-SUBSTITUTED-3-OXADIAZOLYL-1,6-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVES | DAINIPPON PHARMACEUTICAL CO (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-6743803-B2 | SUCH AS ALZHEIMER'S DISEASE AND SCHIZOPHRENIA DUE TO HYPOFUNCTION OF GLUTAMIC ACID RECEPTOR; 5-SUBSTITUTED-3-OXADIAZOLYL-1,6-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVES | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-06-01 | — | — | US | disclosed |
| US-20030166673-A1 | Medicines for the prevention and treatment of neurodegenerative diseases | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1295883-A1 | MEDICINES FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | Dainippon Pharmaceutical Co., Ltd. (JP) | 2003-03-26 | — | — | EP | disclosed |
| US-6277993-B1 | USEFUL AS A BENZODIAZEPINE INVERSE AGONIST, FOR EXAMPLE, AS PSYCHOANALEPTIC DRUG OR DRUG FOR TREATMENT OF DYSMNESIA IN SENILE DEMENTIA OR ALZHEIMER'S DISEASE | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2001-08-21 | — | — | US | disclosed |
| US-6172079-B1 | BENZODIAZEPINE INVERSE AGONISTS; ALZHEIMER*S DISEASE; ANXIOLYTIC AGENTS, SEDATIVES, MUSCLE RELAXANTS, ANTIEPILEPTIC AGENTS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2001-01-09 | — | — | US | disclosed |
| EP-1010699-A1 | 5-SUBSTITUTED-3-OXADIAZOLYL-1,6-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVES | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2000-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275075-A1 | Medicine Comprising a Combination of an Acetylcholinesterase Inhibitor and a 5-Substituted-3-Oxadiazolyl-1,6-Naphthyridin-2(1H)-One Derivative | ACHE, BCHE, CHAT | CDK5 654/4885CDK5R1 446/4885TDO2 1430/4885 |
| US-20030166673-A1 | Medicines for the prevention and treatment of neurodegenerative diseases | GRIN1, GRIN2A, GRM2 | CDK5 1712/4885CDK5R1 1524/4885TDO2 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.